Impact Therapeutics, Inc.

Related records

Trials (19)

• A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
• A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
• A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
• A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
• A Study of IMP4297 in Patients With Advanced Solid Tumors
• A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
• An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
• An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
• An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
• BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
• IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
• IMP4297 Food Effect Trial in Healthy Volunteers
• IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
• Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
• Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer
• Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
• Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
• The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
• The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors